PharmaFocus Today – Page 8 – media

Zhongsheng Pharmaceutical Subsidiary Receives Clinical Trial Approval for New Indication of Class 1 Innovative Drug RAY1225 Injection

Beijing Business Today News – On the evening of January 23, Zhongsheng Pharmaceutical (002317) released an announcement stating that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biological Technology Co., Ltd. (hereinafter referred to as “Zhongsheng Ruichuang”), has received approval from the National Medical Products Administration (NMPA) for a Phase III clinical trial of its self-developed Class 1 innovative peptide drug, RAY1225 Injection. The approval, confirmed via the “Drug Clinical Trial Approval Notice,” covers a new indication: the treatment of “obesity comorbid with obstructive sleep apnea (OSA).” According to the announcement, RAY1225 Injection is an innovatively structured peptide drug with global independent intellectual property rights developed by Zhongsheng Ruichuang. It functions as a dual GLP-1 (Glucagon-like peptide-1) receptor and GIP (Glucose-dependent insulinotropic polypeptide) receptor agonist. Benefiting from its superior pharmacokinetic profile, the drug demonstrates ultra-long-acting potential, supporting a convenient once-every-two-weeks dosing schedule. https://finance.eastmoney.com/a/202601233629301734.html
- Source: drugdu
- 57
- January 26, 2026
Revenue Up 72.57%, HIV Innovative Drug Sales Surge 90.34%

On January 25, Aidea Pharmaceutical (688488.SH) officially released its 2025 annual earnings forecast. During the reporting period, the company maintained strong momentum, achieving “rapid revenue growth and a significant narrowing of losses.” This stellar performance highlights the rising competitiveness of its core business and the effectiveness of its “HIV Innovative Drugs + Human Protein” dual-engine strategy, injecting solid momentum into high-quality, long-term sustainable growth. According to preliminary calculations by the finance department, the company’s 2025 performance saw steady climbs across several key financial indicators: Leapfrog Growth in Revenue Scale Total annual revenue is expected to reach approximately 721.01 million RMB, an increase of about 303.21 million RMB compared to the previous year. This represents a year-on-year (YoY) increase of 72.57%, demonstrating the company’s robust capacity for strategic execution and market expansion. Core Products Continue to Lead The anti-HIV innovative drug business, serving as the core growth engine, performed exceptionally well. ...
- Source: drugdu
- 60
- January 26, 2026
Loxoprofen Sodium Gel Patch Receives Drug Registration Certificate

Fang Sheng Pharmaceutical(603998) announced on the evening of January 25 that its wholly-owned subsidiary, Guangdong Fang Sheng Jian Meng Pharmaceutical Co., Ltd., received a Drug Registration Certificate issued by the National Medical Products Administration on January 23. Loxoprofen sodium gel patch has obtained a drug approval number and can be produced. This drug is suitable for anti-inflammatory and analgesic purposes for osteoarthritis, muscle pain, and post-traumatic swelling and pain. According to the announcement, loxoprofen sodium gel patch is one of the leading-selling analgesics in the Chinese market. Its active ingredient is a phenylpropionic acid nonsteroidal anti-inflammatory drug (NSAID), which has significant anti-inflammatory and analgesic effects. As of the date of the announcement, the project had accumulated an investment of RMB 7.0366 million. According to data from Moshang Pharmaceuticals, the product’s sales in hospitals across all terminals reached RMB 1.349 billion in the first three quarters of 2025, and RMB 1.709 ...
- Source: drugdu
- 73
- January 26, 2026
ASC30 Completes First Dosing in US Phase II Clinical Trial for Diabetes Treatment

On January 26, Ascletis Pharma (01672) announced that it had completed dosing of the first subjects in its Phase II US study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes. Top-line data from the study are expected to be available in the third quarter of 2026. A 13-week study in obese or overweight subjects showed that ASC30 resulted in a placebo-adjusted weight loss of up to 7.7%, with better gastrointestinal tolerability and no liver safety signals observed. The study enrolled 125 obese subjects or overweight subjects with at least one weight-related comorbidity. At the primary endpoint of week 13, once-daily doses of ASC30 tablets at 20 mg, 40 mg, and 60 mg resulted in weight loss of 5.4%, 7.0%, and 7.7%, respectively, which were statistically significant and clinically meaningful. The overall discontinuation rate due to adverse events was 4.8%. ASC30 is the first small molecule ...
- Source: drugdu
- 47
- January 26, 2026
Johnson & Johnson projects its revenue will reach $100 billion by 2026.

Today, Johnson & Johnson released its 2025 financial results. Full-year revenue reached $94.2 billion, a 6.0% increase year-over-year ; net income reached $26.8 billion, with diluted earnings per share (EPS) of $11.03, a 90.5% increase year-over-year; adjusted EPS was $10.79, an 8.1% increase year-over-year. Johnson & Johnson Chairman and CEO Joaquin Duato stated that 2025 will be a pivotal year for the company, marking the beginning of a new era of accelerated growth. The company projects its sales will reach $100 billion by 2026 . In 2022, Pfizer became the first biopharmaceutical company to reach $100 billion in annual revenue. However, since COVID-19 products accounted for more than half of its sales, its revenue surge lasted only one year. Four years later, Johnson & Johnson is also about to reach the $100 billion milestone, and this achievement seems to be more sustainable. Johnson & Johnson’s current business consists of two ...
- Source: drugdu
- 68
- January 26, 2026
Eli Lilly’s “miracle weight-loss drug” targets a new trillion-dollar market; is it about to revolutionize the liver disease treatment landscape?

Recently, according to the CDE (Center for Drug Evaluation) website, Eli Lilly’s GIP/GLP-1 dual receptor agonist, “Telborpeptide Injection,” is proposed for inclusion in the Breakthrough Therapy designation for the treatment of metabolic-associated fatty liver disease (MASH). This marks the fourth major market for Telborpeptide in China. Previously, it has been approved in China for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea. This proposed inclusion in the Breakthrough Therapy designation signifies its significant advantages in treating MASH, and its market launch is expected to be significantly accelerated. MASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, leading to inflammation and fibrosis. Approximately one-third of overweight or obese individuals may have MASH. However, the path to drug development for MASH has been exceptionally arduous, with a complex pathogenesis that has caused numerous pharmaceutical giants to fail over the past few decades, ...
- Source: drugdu
- 90
- January 26, 2026
Xijing Zhiyuan Secures Over 200 Million Yuan in Series B Funding to Accelerate Clinical Development of Solid Tumor TCR-T Therapies

Recently, Xijing Zhiyuan Biotech (Suzhou) Co., Ltd. (hereinafter referred to as “Xijing Zhiyuan” or the “Company”), an innovative enterprise focused on the development of TCR-T immune cell therapy drugs for solid tumors, announced the completion of a Series B financing round exceeding RMB 200 million. The round was co-led by Apricot Capital and a well-known industry fund, with participation from Delian Capital, Yuanhe Holdings, and Suzhou Angel Mother Fund, as well as continued strong support from existing shareholders Ton Hi Capital and GEM Co., Ltd. Halo Capital served as the exclusive financial advisor for this round of financing. Founded in 2020 and headquartered in Suzhou, Xijing Zhiyuan is an innovative enterprise dedicated to the development of TCR-T immune cell therapy drugs for solid tumors. The Company has independently developed a high-throughput, high-sensitivity target antigen–natural TCR discovery platform. By combining computational and experimental validation with iterative feedback, it efficiently screens for ...
- Source: drugdu
- 65
- January 26, 2026
India’s Generic Giant Secures Semaglutide Nod; Local GLP-1 Market Hits $1.2 Billion

As the March 2026 patent cliff approaches, the fiercest battle in the global GLP-1 market is quietly taking shape in India. Over the past three years, few sectors in the global pharmaceutical industry have sustained such wealth myths as GLP-1 weight-loss and diabetes drugs; from Europe and the U.S. to Asia, semaglutide has rapidly evolved from a prescription medicine into a social issue, while beneath this wave India—known as the “world’s pharmacy”—is brewing a systemic shock powerful enough to rewrite the pricing structure. According to the latest court developments, with Novo Nordisk’s core patents entering their final countdown, major Indian generic drugmakers are fully in place, and a multi-billion-dollar battle for dominance in the GLP-1 market is waiting only for the starting gun. All attention is focused on a clear date: March 20, 2026, which is when a key semaglutide patent expires in India and is also seen as the ...
- Source: drugdu
- 85
- January 26, 2026
RiboBio’s ApoC3-Targeting siRNA Drug RBD5044 Granted Implicit Approval for Phase II Clinical Trials in China

Suzhou RiboLife Sciences Co., Ltd. (RiboLife Sciences, Hong Kong Stock Exchange: 06938) announced that RBD5044, a novel siRNA drug targeting ApoC3 independently developed by the Company, received Implicit Approval for Phase II Clinical Trials from the National Medical Products Administration (NMPA) on January 22, 2026. RBD5044 is a small nucleic acid drug for the treatment of hypertriglyceridemia developed based on the RiboGalSTAR™ liver‑targeting technology platform, and is also the second ApoC3‑targeting siRNA globally to enter clinical development. Available Phase I clinical data show that a single administration achieved significant inhibition of apolipoprotein C3 (ApoC3) by up to 84%, accompanied by a reduction in triglyceride (TG) levels of up to 70%. Furthermore, during the 6‑month follow‑up period, subjects’ TG levels remained stably below 50% of baseline, and overall lipid profiles were comprehensively improved. Meanwhile, RBD5044 demonstrated favorable tolerability, with no dose‑dependent adverse events or elevated liver enzymes observed even at ...
- Source: drugdu
- 68
- January 23, 2026
A new generation of ophthalmic dual antibodies challenges Roche’s dominant position.

Ollin recently released early data on its VEGF/Ang2 bispecific antibody OLN324 against Roche’s blockbuster product Vabysmo. The results showed that nearly 90% of patients with diabetic macular edema (DME) achieved lesion resolution within 12 weeks , while Roche’s Vabysmo only achieved 57% in the same metric. This means that the drug has the potential to cause lesion reversal and revolutionize the treatment of retinal diseases. 01 Head-to-head challenge against Roche’s pharmaceutical giant head-to-head phase 1b clinical trial conducted in multiple centers in the United States . It enrolled more than 160 patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME) and compared the efficacy and safety of IBI324 with Vabysmo (faricimab). Results showed that at week 12, nearly 90% of patients with DME treated with OLN324 4 mg achieved DME elimination (defined as central retinal thickness CST < 325 μm), compared to 57% in the faricimab group ...
- Source: drugdu
- 91
- January 23, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.